Background: In previous studies, teriflunomide significantly reduced the annualised relapse
rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study …

Objective: To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β
(IFNβ) in patients with relapsing forms of multiple sclerosis (RMS). Methods: A total of 118 …

Background Teriflunomide is a new oral disease-modifying therapy for relapsing forms of
multiple sclerosis. Methods We concluded a randomized trial involving 1088 patients with …

Background: The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-
blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly …

Background Teriflunomide is an oral disease-modifying therapy approved for treatment of
relapsing or relapsing–remitting multiple sclerosis. We aimed to provide further evidence for …

Background: Teriflunomide, an oral disease-modifying therapy in development for patients
with relapsing forms of multiple sclerosis (RMS), was well tolerated and effective in reducing …

Background Teriflunomide, a once-daily oral immunomodulator for the treatment of
relapsing-remitting multiple sclerosis, has demonstrated consistent efficacy on clinical and …

In the prevention of relapses and disability by interferon subcutaneously in multiple sclerosis
(PRISMS) study, 560 patients with relapsing–remitting multiple sclerosis were randomized to …

Background Studies evaluating interferon beta (IFNβ) for multiple sclerosis (MS) showed
only partial efficacy. In many patients, IFNβ does not halt relapses or disability progression …

In separate clinical trials, two preparations of recombinant interferon (IFN)-beta, IFN beta-1a
and IFN beta-1b, reduced exacerbation rates in relapsing-remitting multiple sclerosis (RR …